The U.S. Food and Drug Administration announced it will remove or narrow boxed warnings on hormone replacement therapy (HRT) products for menopause after concluding earlier label risks were overstated. Agency officials said updated labeling will reflect current evidence on cardiovascular and cancer risks and is intended to increase appropriate clinical access to menopausal hormone treatments. Health officials and professional societies reacted with a mix of support and caution: proponents cited improved access for symptomatic patients, while some clinicians urged clear guidance to avoid misinterpretation about indications and long-term benefits. The agency requested manufacturers to submit revised labeling and is coordinating communications to ensure prescribers and patients understand the updated safety profile.